Abstract
Hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN) is a rare and multisystemic disease. Scarce evidence about its economic burden has been published, especially regarding carriers and early stage patients. To characterize these populations, a descriptive study was developed in Spain. Secondary endpoints were estimation of the use and costs of healthcare resource utilization (HRU) and estimation of indirect costs from a societal perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.